Combining selumetinib with an FGFR3 inhibitor (PD173074) significantly reduced the tumor volumes and weight in HNSCC xenografts.349 DEL-22379, a relatively specific ERK inhibitor, showed remarkable anticancer efficiency in BRAF-mutant anaplastic thyroid cancer in vivo and was a candidate target for cancer therapy.350. Here, BRAF is linked to cancer.